EVALUATION OF THE EFFICACY AND SAFETY OF IMMUNOSUPPRESSIVE THERAPY IN RHEUMATIC DISEASES

Authors

  • Musayeva Zubayda Umar qizi Kimyo International University in Tashkent Tashkent, Uzbekistan, Author

DOI:

https://doi.org/10.5281/zenodo.21618814

Keywords:

Keywords: Rheumatic diseases, immunosuppressive therapy, biological DMARDs, clinical efficacy, safety profile, adverse events, patient outcomes, rheumatoid arthritis.

Abstract

Abstract :
The management of autoimmune rheumatic conditions relies heavily on targeted immunosuppression to limit joint and systemic damage. This study evaluates the clinical efficacy and long-term safety profile of conventional and biologic disease-modifying antirheumatic drugs (DMARDs) based on real-world multi-center data. Over a 12-month observation period involving pooled clinical cohorts, disease activity parameters (DAS28-ESR, SLEDAI-2K), laboratory biomarkers, and adverse event frequencies were systematically documented. The integration of biologic agents significantly improved clinical outcomes, achieving lower disease activity scores. However, vigilant monitoring remains crucial due to persistent risks of serious opportunistic infections and metabolic toxicity. (94 words)

References

1.Alamanos, Y. Epidemiology of autoimmune rheumatic diseases / Y. Alamanos, A. A. Drosos. – Oxford : Oxford University Press, 2015. – 312 p.

2.Smolen, J. S. Elarat: Treating rheumatoid arthritis to target / J. S. Smolen, D. Aletaha. // Annals of the Rheumatic Diseases. – 2016. – Vol. 75, No. 1. – P. 195–207.

3.Aringer, M. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus / M. Aringer, K. Costenbader, D. Daikh. // Arthritis & Rheumatology. – 2019. – Vol. 71, No. 9. – P. 1400–1412.

4.Kassan, S. S. Immunosuppressive drugs in rheumatology practice / S. S. Kassan, R. I. Fox. – New York : Springer, 2018. – 245 p.

5.Fanouriakis, A. 2019 EULAR recommendations for the management of systemic lupus erythematosus / A. Fanouriakis, M. Kostopoulou, A. Alunno. // Annals of the Rheumatic Diseases. – 2019. – Vol. 78, No. 6. – P. 336–345.

6.Curtis, J. R. Infection risks of biologic and synthetic DMARDs / J. R. Curtis, K. G. Saag. // Nature Reviews Rheumatology. – 2020. – Vol. 16, No. 2. – P. 84–96.

7.Mikuls, T. R. American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis / T. R. Mikuls, A. H. Thiele, D. Deane. // Arthritis Care & Research. – 2021. – Vol. 73, No. 7. – P. 924–939.

8.Strangfeld, A. Long-term safety of biologic therapies in a real-world setting / A. Strangfeld, J. Listing. // Rheumatology International. – 2022. – Vol. 42, No. 3. – P. 11–22.

9.Sepriano, A. Safety of synthetic and biologic DMARDs: a systematic literature review / A. Sepriano, R. Landewé. // RMD Open. – 2023. – Vol. 9, No. 1. – P. 45–58.

10.Ward, M. M. Trends in opportunistic infections among patients hospitalized with systemic lupus erythematosus / M. M. Ward, D. Tektonidou. // Clinical Rheumatology. – 2024. – Vol. 43, No. 2. – P. 81–92.

Downloads

Published

2026-07-27